Tag Archives: LOXO

Ignyta: ROS1 Lung Cancer Update Causing Shares To Break Out

Shares of Ignyta (NASDAQ:RXDX) have more than doubled over the past year, with news in May that the company received the coveted Breakthrough Therapy Designation for entrectinib providing momentum for the next leg up.

RXDX data by YCharts

The drug candidate received the designation for the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in....More>>>

25 Stocks Moving In Monday's Pre-Market Session

Gainers Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate. Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination....More>>>